Antibiotic Resistance to Shiga Toxin-Producing E. coli on the Rise

Shiga toxin-producing Escherichia coli (STEC) is showing increased antibiotic resistance linked to the use of growth promoters in livestock, according to research in Antibiotics (Basel) and Emerging Infectious Disease. These antimicrobial agents trigger bacterial responses that spread toxin-encoding phages, potentially making human foodborne gastroenteritis harder to treat with conventional medicines.

The rise in resistance is tied to the routine use of antibiotics in food-producing animals to prevent infectious diseases and promote growth. According to a study published March 24, 2021, in Antibiotics (Basel), the extensive use of these drugs in agriculture selects for resistant bacteria. These strains can then enter the human food chain, increasing the risk of foodborne illnesses that are less likely to respond to standard antibiotic treatments.

How do bovine growth promoters drive resistance?

Bovine antibiotic growth promoters (bAGPs) contribute to the expansion of pathogenic bacteria through a specific biological trigger. Research published May 5, 2016, in the journal Emerging Infectious Disease, found that sublethal concentrations of bAGPs can trigger the SOS response system in E. coli O157:H7.

This SOS response facilitates the propagation and spread of Shiga toxin (Stx)-encoding phages. When E. coli O157:H7 is co-cultured with other E. coli isolated from cattle in the presence of these promoters, it significantly increases the emergence of non-O157, Stx-producing E. coli.

The study identified specific antimicrobial agents that are most effective at mediating this transmission. Oxytetracycline and chlortetracycline, both commonly used in agricultural settings, induced the most substantial transmission of Stx phages.

Why does this affect human food safety?

STEC is an enteric pathogen known to cause human gastroenteritis outbreaks. The transition of resistant strains from livestock to humans creates a significant public health challenge because the bacteria are selected for resistance before they ever reach the consumer.

When these resistant bacteria enter the food chain, the resulting infections are more difficult to manage in a hospital setting. The research in Antibiotics (Basel) emphasizes that these infections are less likely to respond to conventional antibiotics, which can complicate recovery and increase the severity of the outbreak.

What are the risks of non-O157 STEC strains?

While E. coli O157:H7 is a well-known cause of foodborne illness, the use of bAGPs expands the variety of dangerous strains. The 2016 Emerging Infectious Disease study highlights that the trigger of the SOS response doesn’t just maintain existing strains but actively promotes the emergence of non-O157, Stx-producing E. coli.

This expansion means that a wider array of E. coli strains can produce the Shiga toxin responsible for severe gastrointestinal distress. The combination of increased strain diversity and heightened antibiotic resistance makes the monitoring and treatment of STEC infections more complex for health providers.

The evidence suggests a direct link between subtherapeutic feed supplements used for livestock growth and the increased prevalence of pathogenic, resistant bacteria in the environment. This mechanism ensures that the bacteria are not only toxin-producing but are also equipped to survive the very antibiotics intended to treat the infections they cause in humans.